| Drug
Information |
| Name | CIPEMASTAT |
| Synonyms | CIPEMASTAT |
| Indication | Not Available | Experimental |
| Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
|
| InChI | 1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16
(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H
3,(H,23,27)/t16-,17+/m1/s1 |
| InChIKey | GFUITADOEPNRML-SJORKVTESA-N |
| Canonical SMILES | CC1(C(=O)N(C(=O)N1C)CC(C(CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C |
| Isomeric SMILES | CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C |
| Target | ADAM17 |  | Inhibitor | [1] |
| Matrix metalloproteinase 13 | | Inhibitor | [1] |
| Matrix metalloproteinase 3 | | Inhibitor | [1] |
| Matrix metalloproteinase 8 | | Inhibitor | [2] |
| Matrix metalloproteinase 9 | | Inhibitor | [2] |
| Matrix metalloproteinase-1 | | Inhibitor | [1] |
| Matrix metalloproteinase-2 | | Inhibitor | [2] |
| Ref 1 | Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6. Epub 2006 Mar 3.A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. To Reference |
| Ref 2 | J Med Chem. 2000 Feb 10;43(3):305-41.Protease inhibitors: current status and future prospects. To Reference |
